Pirfenidone in idiopathic pulmonary fibrosis: a guide to its use in the EU
| Autor: | Katherine A. Lyseng-Williamson, Gillian M. Keating, Sarah L. Greig, Esther S. Kim |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Vital capacity
medicine.medical_specialty business.industry Pharmacy Pirfenidone respiratory system medicine.disease Gastroenterology respiratory tract diseases Surgery Clinical trial 03 medical and health sciences Idiopathic pulmonary fibrosis 0302 clinical medicine Pharmacotherapy 030228 respiratory system Tolerability Internal medicine Tissue fibrosis medicine Pharmacology (medical) 030212 general & internal medicine business medicine.drug |
| Zdroj: | Drugs & Therapy Perspectives. 32:323-329 |
| ISSN: | 1179-1977 1172-0360 |
| DOI: | 10.1007/s40267-016-0321-6 |
| Popis: | Pirfenidone (Esbriet®), a synthetic pyridine compound with antifibrotic, anti-inflammatory and antioxidant properties that inhibit the progression of tissue fibrosis, is indicated for the treatment of idiopathic pulmonary fibrosis (IPF). In clinical trials in patients with mild to moderate IPF, oral pirfenidone generally provided a reduced rate of decline in forced vital capacity, while prolonging progression-free survival and reducing the risk of IPF-related and all-cause mortality. Pirfenidone has a manageable tolerability profile; however, gastrointestinal and skin-related events are common. Data from longer-term and real-world studies of pirfenidone use in patients with IPF are consistent with those in clinical trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink